Aska Pharmaceutical Co

Aska Pharmaceutical Co., a Japan-based pharmaceutical preparation manufacturing company, reported approximately 10,780,000 kg CO2e in combined Scope 1 and Scope 2 emissions for 2022. This comprised 6,687,000 kg CO2e from Scope 1 emissions and 4,093,000 kg CO2e from Scope 2 emissions.

In comparison, their 2021 emissions were approximately 12,251,000 kg CO2e (7,209,000 kg CO2e Scope 1 and 5,042,000 kg CO2e Scope 2). For 2020, total emissions were around 13,215,000 kg CO2e (7,443,000 kg CO2e Scope 1 and 5,771,000 kg CO2e Scope 2). Data for 2019 indicates approximately 13,215,000 kg CO2e, and for 2013, approximately 17,726,000 kg CO2e, though specific scope breakdowns are not available for these earlier years.

Aska Pharmaceutical Co. has disclosed Scope 1 and Scope 2 emissions for recent years, but no Scope 3 emissions data is currently available. The company has not publicly reported any specific emissions reduction targets, Science Based Targets initiative (SBTi) commitments, or climate pledges.